Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REMDESIVIR: 10,501 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
10,501
Total FAERS Reports
2,729 (26.0%)
Deaths Reported
2,556
Hospitalizations
10,501
As Primary/Secondary Suspect
883
Life-Threatening
127
Disabilities
Oct 22, 2020
FDA Approved
Gilead Sciences, Inc.
Manufacturer
Prescription
Status

Drug Class: SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] · Route: INTRAVENOUS · Manufacturer: Gilead Sciences, Inc. · FDA Application: 214787 · HUMAN PRESCRIPTION DRUG · FDA Label: Available

Patent Expires: Sep 6, 2029 · First Report: 19400901 · Latest Report: 20250803

What Are the Most Common REMDESIVIR Side Effects?

#1 Most Reported
Off label use
1,092 reports (10.4%)
#2 Most Reported
Alanine aminotransferase increased
1,047 reports (10.0%)
#3 Most Reported
Death
808 reports (7.7%)

All REMDESIVIR Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Off label use 1,092 10.4% 201 515
Alanine aminotransferase increased 1,047 10.0% 72 114
Death 808 7.7% 803 100
Aspartate aminotransferase increased 713 6.8% 55 102
Bradycardia 652 6.2% 55 142
Acute kidney injury 605 5.8% 231 177
Covid-19 570 5.4% 328 278
Drug ineffective 497 4.7% 242 300
Liver function test increased 447 4.3% 30 67
Respiratory failure 394 3.8% 275 117
Blood creatinine increased 359 3.4% 83 79
Condition aggravated 318 3.0% 133 93
Covid-19 pneumonia 280 2.7% 166 136
Renal impairment 258 2.5% 85 84
Hypotension 254 2.4% 102 40
Cardiac arrest 235 2.2% 182 59
Hepatic enzyme increased 226 2.2% 25 32
Therapy cessation 215 2.1% 13 29
Drug ineffective for unapproved indication 212 2.0% 61 181
Pneumonia 212 2.0% 84 75

Who Reports REMDESIVIR Side Effects? Age & Gender Data

Gender: 39.8% female, 60.2% male. Average age: 61.7 years. Most reports from: US. View detailed demographics →

Is REMDESIVIR Getting Safer? Reports by Year